Oral Pulmonary Arterial Hypertension-Targeted Therapy in Patients With Pulmonary Hypertension due to Interstitial Lung Disease.

A pilot trial published in 2012 showed that the use of riociguat led to improvement in PVR and CO, but these findings did not reach statistical significance and the subsequent RISE-IIP randomized controlled trial (RCT) revealed significant harm and increased mortality associated with use in PH-ILD [ 20 , 21 ].

also in 111,027 other papers